2024 年业绩符合市场预期公司公布2024 年业绩：收入288.66 亿元，同比增长10.2%；归母净利润35.00 亿元，同比增长50.1%，经调整归母净利润34.57 亿元，同比增长33.5%，符合市场预期。发展趋势收入稳健增长，优势治疗领域地位稳固。分治疗领域看，2024 年公司肿瘤领域收入107.34 亿元（YoY+22.0%），肝病领域收入34.38 亿元（YoY-10.1%），呼吸...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.